Showing results (291-300 of 308) with videos related to
Sort By:
Pageof 31
Frontiers in Neurology|January 10, 2022
A Preliminary DTI Tractography Study of Developmental Neuroplasticity 5-15 Years After Early Childhood Traumatic Brain InjuryElisabeth A Wilde, Ilirjana Hyseni, Hannah M Lindsey, et al.ACS Medicinal Chemistry Letters|May 6, 2015
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonistsChristine Yang, Jaume Balsells, Hong D Chu, et al.JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.Brain Injury|November 12, 2016
Quantitative structural neuroimaging of mild traumatic brain injury in the Chronic Effects of Neurotrauma Consortium (CENC): Comparison of volumetric data within and across scannersElisabeth A Wilde, Erin D Bigler, Trevor Huff, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 17, 2004
A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignanciesS I Shibata, R Pezner, D Chu, et al.Cancers|March 29, 2023
Cognitive Sparing in Proton versus Photon Radiotherapy for Pediatric Brain Tumor Is Associated with White Matter Integrity: An Exploratory StudyLisa E Mash, Lisa S Kahalley, Kimberly P Raghubar, et al.Frontiers in Immunology|August 18, 2025
Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosaJillian Eisenhauer, Spencer Dublin, Jihae Choi, et al.Journal of Visualized Experiments : Jove|June 2, 2020
A Salt-Templated Synthesis Method for Porous Platinum-based Macrobeams and MacrotubesF John Burpo, Anchor R Losch, Enoch A Nagelli, et al.Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.Pageof 31